Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow (2016 - 2025)

Capricor Therapeutics has reported Net Cash Flow over the past 15 years, most recently at $268.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $268.3 million for Q4 2025, up 570.02% from a year ago — trailing twelve months through Dec 2025 was $276.6 million (up 8215.36% YoY), and the annual figure for FY2025 was $276.6 million, up 8215.36%.
  • Net Cash Flow for Q4 2025 was $268.3 million at Capricor Therapeutics, up from -$3.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CAPR hit a ceiling of $268.3 million in Q4 2025 and a floor of -$57.1 million in Q4 2024.
  • Median Net Cash Flow over the past 5 years was $116945.5 (2023), compared with a mean of $12.8 million.
  • Peak annual rise in Net Cash Flow hit 6867.31% in 2024, while the deepest fall reached 1099.8% in 2024.
  • Capricor Therapeutics' Net Cash Flow stood at -$6.0 million in 2021, then soared by 119.98% to $1.2 million in 2022, then surged by 380.01% to $5.7 million in 2023, then tumbled by 1099.8% to -$57.1 million in 2024, then soared by 570.02% to $268.3 million in 2025.
  • The last three reported values for Net Cash Flow were $268.3 million (Q4 2025), -$3.7 million (Q3 2025), and -$5.6 million (Q2 2025) per Business Quant data.